Introduction {#Sec1}
============

Cancer cachexia affects a majority of cancer patients and has a considerable negative impact on quality of life, physical function, anticancer treatment response, and survival \[[@CR1]\]. The lack of a common definition hindered the understanding of the cachexia pathophysiology and the development of treatment strategies \[[@CR2]\]. An international consensus recently defined cancer cachexia as a multifactorial syndrome characterized by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment. The pathophysiology of cancer cachexia is characterized by a negative protein and energy balance due to a variable degree of reduced food intake and deranged metabolism \[[@CR3]\]. Currently, there is no standard treatment for cachexia available \[[@CR4]\].

A number of symptoms and complications of advanced cancer, anticancer treatment, or medical co-morbidities \[[@CR5]\] can interfere with patients' appetite and ability to eat or digest food \[[@CR6]\]. The broad spectrum of impediments to oral nutritional intake can be conceptualized as nutrition impact symptoms (NIS) \[[@CR7]\].

NIS seem to occur frequently in clinical care \[[@CR8]\], such as taste and smell alterations \[[@CR9]\], mucositis \[[@CR10]\], nausea \[[@CR11]\], constipation \[[@CR12]\], pain and its treatment \[[@CR13]\], or shortness of breath \[[@CR14]\]. Despite the impact of these causes on oral nutritional intake, they have rarely been systematically assessed and original research has so far focused either on brief nutritional screening instruments or on comprehensive assessments of nutritional problems \[[@CR15]\]. The systematic assessment and treatment of NIS merits further evaluation since the majority of these symptoms can be treated by supportive care measures and their negative impact on oral nutritional intake may be potentially halted \[[@CR16]\]. Widely used nutrition assessment instruments such as the PG-SGA (Patient-Generated Subjective Global Assessment) cover NIS to some extent \[[@CR17]\]. The PG-SGA assesses 14 symptoms that keep the patient from eating (anorexia, nausea, vomiting, constipation, diarrhea, mouth sores, dry mouth, problems with taste, smell, or swallowing, early satiety, pain, fatigue, and other reasons) \[[@CR18]\]. An evaluation of the PG-SGA NIS assessment showed high numbers of patient-reported symptoms that keep them from eating, e.g., anorexia 47 %, early satiety 43 %, nausea 20 %, and abnormal taste 20 % \[[@CR19]\]. A correlation between number of NIS and low nutritional status has been reported \[[@CR20]\], and the PG-SGA does predict nutritional risk in patients receiving chemotherapy \[[@CR21]\], hospital stay \[[@CR22]\], and patient prognosis \[[@CR23]\]. The score also leads to (overall) nutritional triage recommendations in patients having various tumor types \[[@CR18]\], an important help considering that a recent survey of oncologists suggested that awareness of nutritional issues in oncology may merit improvement \[[@CR24]\].

In a recent publication, the prevalence and relationship of NIS were evaluated in head and neck cancer patients by means of the PG-SGA. NIS such as anorexia, mouth sores, or dysphagia were found to be significant predictors of reduced oral dietary intake \[[@CR7]\]. Although the PG-SGA covers these NIS, the assessment done by a healthcare professional generates a score based on four domains: history of weight loss, estimation of functional status, physical examination, and the list of 14 symptoms. Each of the 14 symptoms assessed in the PG-SGA is graded and adds between one and three points per symptoms (total of 24 points for the entire NIS checklist) to the global PG-SGA score. Whether NIS in the PG-SGA score will trigger specific interventions has not been tested and the relationship for the individual NIS and impaired oral nutritional intake is not fully understood \[[@CR25]\].

This study aims to explore the patient-reported frequency of NIS in a mixed advanced cancer patient population by means of a subjective quantitative NIS checklist.

As an exploratory objective, we aim to generate evidence for the practice-guiding potential of the checklist.

Methods {#Sec2}
=======

The frequency of NIS was evaluated in a cross-sectional study of outpatients. To appraise the practice-guiding potential, a case--control study in the outpatient clinic was performed. The study was approved by the local ethics review board.

NIS checklist {#Sec3}
-------------

This first version of the NIS checklist was developed based on a literature review, multiprofessional clinical expert opinions, and clinical experience. The checklist was piloted and continuously improved. A number of clinical symptoms and syndromes having a potential negative impact on oral nutritional intake were included.

Anorexia and early satiety were considered to be directly cachexia associated and therefore not included in the checklist (Table [1](#Tab1){ref-type="table"}). Eight symptoms potentially affect the function or integrity of the gastrointestinal tract from mouth to anus: stomatitis, taste and smell alterations dysphagia, epigastric pain, abdominal pain, constipation, diarrhea, and defecation after meal. Four other complex syndromes can be associated with decreased nutritional intake: pain, dyspnea, fatigue, and depression/anxiety. In order to keep the checklist short, an open question was added in order to allow patients to report individual-specific NIS.Table 1Translation of version 1 of the NIS checklist as used in this studyI have reduced appetite and/or reduced oral intake because ofNone (1)Little (2)Moderate (3)A lot (4)StomatitisTaste and smell alterationsDysphagiaPain in the stomachAbdominal painConstipation (better appetite after bowel movements)DiarrheaDefecation after mealsPainDyspneaFatigueOther reasons

The final checklist consists of one page and the items are filled in by the patients. A four categorical scale was chosen. Patients answered 12 questions "I have reduced appetite and/or reduced oral intake because of each of the symptoms", e.g., taste and smell alterations by checking one of the four choices: 1 = none, 2 = little, 3 = moderate, 4 = a lot. A threshold of three or more was chosen and considered significant for this study based on clinical experience and patients' interviews in the development phase.

Patient populations {#Sec4}
-------------------

### Case patients {#d29e545}

The first group included subjects from the nutrition-fatigue clinic, which is a specialized interdisciplinary outpatient clinic for advanced cancer patients, having as predominant problems one or more of the following: involuntary loss of weight, appetite, or fatigue. Family members are an important component of the nutrition-fatigue clinic evaluation. The aim of this clinic is to perform multidimensional in-depth assessments by specialized nurses, nutritionists, psycho-oncologists, and palliative oncology specialists, tapping the potential of interdisciplinary team interactions, as well as offering tailored symptom control. Predefined assessment instruments include the Edmonton Symptom Assessment Scale \[11 categorical scale (0 = none, 10 = worst)\] \[[@CR26]\], NIS checklist, screening questions for eating-related distress \[[@CR27]\], Hamilton Anxiety/Depression Scale \[[@CR28]\], three single-item fatigue-domain questions \[[@CR29]\], 2-day food protocols, and a structured interview for the social support situation \[[@CR30]\].

### Control patients {#d29e565}

We matched patients from the routine medical oncology outpatient clinic, retrieved from the alphabetical electronic database by hand-search starting at "A". Patients were matched for tumor type (using the etiological groups---gastrointestinal, urogenital, lung, breast, prostate, mesothelioma, lymphoma, and ear--nose--throat), age (decade), tumor stage (I--IV), and gender. Symptom severity was assessed by the treating oncologists by means of a five categorical scale (0 = none, 1 = mild, 2 = moderate, 3 = strong, 4 = very strong) as routinely used since many years. To retrieve patients comparable to the patients from the nutrition-fatigue clinic, the inclusion criteria for the control patients were either fatigue or anorexia \[rated as mild (1) to very strong (4)\] or documented IWL (\>2 % in 2 months or \>5 % in 6 months). In none of the control patients the NIS checklist was used.

Frequency of NIS {#Sec5}
----------------

The number of patients from the nutrition-fatigue clinic having scores of the NIS checklist above the threshold of 3 or more was assessed.

Case--control comparison of a practice-guiding potential of the NIS checklist {#Sec6}
-----------------------------------------------------------------------------

The charts of the matched patients from the nutrition-fatigue clinic and the routine oncology outpatient clinics were reviewed for the period of 2 weeks before and 2 weeks after the inclusion time point by two researchers applying a structured assessment template. Therapeutic interventions for NIS were defined as either:Intention to ameliorate anorexia or cachexia specifically mentioned by the physician, orChange or new onset of medication (e.g., laxatives, mouth care) or therapeutic counseling (e.g., nutritional, physiotherapy) for stomatitis, taste and smell alterations, dysphagia, epigastric or abdominal pain, constipation or diarrhea, or symptom control of pain, dyspnea, or fatigue.

Inconsistent chart review findings were discussed until consensus was reached (AO, FS, JW).

Statistical analysis {#Sec7}
====================

The distribution of age as well as weight loss, body mass index (BMI), and C-reactive protein by patient cohort were analyzed using a Mann--Whitney *U* test, while the distributions of gender by cohort was compared using a chi-square test.

To compare system load score among the two cohorts, all scores were standardized to a scale from 0 to 100. A Mann--Whitney *U* test was then performed on each of the symptom scores separately to assess if there were significant differences among the cohorts.

Comparison of frequency of intervention for each symptom was also performed using Fisher's exact test on a per symptom basis, and *p* values were adjusted using the Bonferroni correction.

The number of identified therapeutic interventions for NIS was compared between the patients treated in the nutrition-fatigue clinic and the case-matched controls. All analysis was performed in the R programming language.

Results {#Sec8}
=======

Patients from the nutrition-fatigue clinic and the control patients were all outpatients. As the control patients were matched (age, sex, and tumor type), no differences are reported regarding these parameters. CRP did not differ significantly in the two groups (*p* = 0.68); however, patients from the nutrition-fatigue clinic had a significantly lower body mass index (BMI, *p* \< 0.0001) and a trend towards weight loss was seen (*p* = 0.056) (Table [2](#Tab2){ref-type="table"}). All patients had advanced tumor stage III or IV. No data on survival of these patients are available.Table 2Patient characteristics for patients from the nutrition-fatigue clinic and the matched control patientsNutrition-fatigue clinic (*n* = 52)Control patients (*n* = 52)*p* valueAge, yearsMedian6364Range25--8626--810.35Sex Male3131 Female21210.99Primary tumor site*N*%*N*%Gastrointestinal *n* (%)16311631Urogenital *n* (%)2424Lymphoma *n* (%)612612Breast *n* (%)4848Lung *n* (%)11211121ENT *n* (%)3434Prostate *n* (%)917917Mesothelioma *n* (%)1212C-reactive protein (CRP, mg/l)Median13110.68Range1--1151--132Mean body mass index (kg/m^2^)22.4 ± 3.724.9 ± 3.70.0001Range14.5--31.317.3--34.3Patients with weight loss ≥2% in prior 2 months (*N*/%)28/70 %28/70 %Mean value of weight loss in prior 2 months (%)4.72.80.056Range−8.9--32.9−3.8--14.8

Standardized symptom load scores were compared. For anorexia and dyspnea, the two groups were comparable (*p* = 0.44 and 0.63, respectively). For pain (*p* \< 0.0001), nausea (*p* = 0.003), and fatigue (*p* = 0.002), a statistically significant higher symptom load was seen in the nutrition-fatigue clinic patient population compared to the control patients (Table [3](#Tab3){ref-type="table"}).Table 3Symptom load in the nutrition-fatigue clinic patients compared to the matched patient populationNutrition-fatigue clinic (*n* = 52)Control patients (*n* = 52)Symptom load (mean ± SD):*p* valueAnorexia32.7 ± 23.430.4 ± 18.90.44Pain53.8 ± 29.317.9 ± 18.5\<0.0001Fatigue52.5 ± 28.426.0 ± 29.30.002Nausea17.9 ± 23.35.9 ± 13.80.003Dyspnea11.7 ± 19.211.7 ± 19.20.63

Frequency of NIS {#Sec9}
----------------

The most frequent patient-reported NIS in the nutrition-fatigue clinic patients were taste and smell alterations (27 %), constipation (19 %), abdominal pain (13.5 %), and dysphagia (11.5 %) (Table [4](#Tab4){ref-type="table"}). Very few NIS were reported to the open question, among which nausea, emesis, general anxiety, and uncertainty were mentioned in single cases.Table 4Frequency of nutrition impact symptoms (NIS) rated as 3 (moderate) and 4 (a lot) by the NIS checklist in patients assessed in the nutrition-fatigue clinicNutrition-fatigue clinic (*n* = 52; percentage)*N*%Stomatitis47.7Taste and smell alterations1426.9Dysphagia611.5Epigastric pain59.6Abdominal pain713.5Constipation1019.2Diarrhea47.7Defecation after meal35.8Pain35.8Dyspnea00Fatigue59.6

Of the nutrition-fatigue clinic patients, 19 (37 %) reported no relevant NIS (score 1 or 2 on checklist), 15 patients (29 %) one, 11 patients (21 %) two, and seven patients (13 %) three or more NIS.

Case--control comparison of the NIS-specific interventions {#Sec10}
----------------------------------------------------------

Patients in the nutrition-fatigue clinic received therapeutic interventions for the same symptom statistically significant more often than matched control patients (Table [5](#Tab5){ref-type="table"}), e.g., taste and smell alterations (*p* = 0.04), constipation (*p* = 0.01), pain (*p* = 0.0001), and fatigue (*p* = 0.0004). For NIS such as stomatitis, dysphagia, or diarrhea, the number of patients and interventions were too small to detect differences in specific actions taken.Table 5Comparison of the frequency of NIS in the nutrition-fatigue patient population and in the control populationNutrition impact symptomsNutrition-fatigue clinicControl patients*p* valueFrequency and interventions*n* = 52*n* = 52Patients with stomatitis (*n*)43Patients with interventions (*n*)310.49Patients with taste and smell alterations (*n*)147Patients with interventions (*n*)1210.04Patients with dysphagia (*n*)63Patients with interventions (*n*)620.99Patients with epigastric pain (*n*)53Patients with interventions (*n*)320.99Patients with abdominal pain (*n*)76Patients with interventions (*n*)620.10Patients with constipation (*n*)1011Patients with interventions (*n*)1050.01Patients with diarrhea (*n*)46Patient with interventions (*n*)340.56Patients with defecation after meal (*n*)30Patients with interventions (*n*)300.99Patients with pain (*n*)328Patients with interventions (*n*)3160.0001Patients with fatigue (*n*)519Patients with interventions (*n*)480.0004Patients with dyspnea (*n*)015Patients with interventions (*n*)05n.a.

Discussion {#Sec11}
==========

This study reports patient's subjective rating of the impact of NIS on their appetite or oral nutritional intake. Moderate to high impact of NIS on oral intake was reported frequently in this population of patients with mixed advanced cancer. Assessment of NIS seems feasible and has the potential to trigger symptom-specific interventions or examinations.

In advanced cancer patients, NIS are very common reaching up to 50 %, taste and smell alterations being the most common reaching almost 30 %. Not astonishingly, patients admitted to a specialized nutrition-fatigue clinic presented with higher NIS load (taste and smell alterations, dysphagia, and constipation) than the controls in the oncology outpatient clinic. A recent study in a cancer cachexia center confirmed the frequent occurrence of two to three NIS per patient and its association with poor appetite and weight loss \[[@CR31]\].

Most of the reported symptoms were of gastrointestinal origin such as constipation or taste and smell alterations. Patients in our study mentioned constipation as related to impaired nutritional intake in 20 %. In a previous head and neck cancer study population, 10 % of patients related constipation to reduced oral nutritional intake \[[@CR7]\]. It can be hypothesized that in selected tumor types, specific NIS might be more common such as dysphagia and mouth sores in head and neck cancer patients for instance. In our mixed cancer population, head and neck cancer though accounted for 8 % of the total of patients only.

The reason for differences in the documented frequency in the nutrition-fatigue clinic patients compared to the control patients might be that most of these symptoms are not routinely assessed in the local oncological outpatient clinic and/or are not documented in the charts. In case of NIS routinely assessed in a specialty oncological outpatient clinic, the frequency of interventions in patients is comparable (e.g., dysphagia, diarrhea). In contrast, silent symptoms such as taste and smell alterations or even fatigue seem to be frequent but are not always brought forward by the patient or assessed by the oncologist. For symptoms with few therapeutic options, the oncologists might not ask the patient about it unless it is reported spontaneously. The early recognition and treatment of silent symptoms may limit their contribution to the cachexia syndrome.

The use of the NIS checklist in the nutrition-fatigue clinic triggered more therapeutic interventions compared with the control population (Table [5](#Tab5){ref-type="table"}). The highest incidence of reported interventions with a significant difference compared to the control patients was seen in taste and smells alterations (85 % vs. 14 %), constipation (100 % vs. 45 %), pain (100 % vs. 57 %), and fatigue (80 % vs. 42 %).

This is, to our knowledge, the first study to systematically assess and report NIS-specific interventions. This approach was chosen in order to evaluate the triggered NIS-specific interventions leading ideally to better symptom control. While the effectiveness of NIS-specific interventions was not assessed in our study, it can be hypothesized that interventions may positively impact nutritional intake.

A major limitation is the development of the checklist. It has to be noted that anorexia and early satiety and a number of symptoms potentially affecting appetite such as nausea, vomiting, or depression were not included. Most causes assessed with the NIS checklist could also be evaluated using the PG-SGA \[[@CR15]\]. It can be argued that the use of the widely used PG-SGA would have generated more comparable results. Our checklist was based on literature review and expert opinion and continuously tested in our clinic. Similar other tools are being used in other clinics (e.g., MD Anderson Cancer Center) and a common standard is not yet established.

The rating of the specific impact on nutritional intake of different symptoms at the same time may be too complex for an advanced cancer population. To encounter this, the actual version of checklist in use in our clinics is asking in a two-step procedure whether a symptom was present in the past 7 days and in a second step whether it had an impact on oral nutritional intake. However, symptoms should be treated regardless of their impact on oral intake.

Other limitations are the mixed cancer patient population in which the NIS assessment was performed resulting in different numbers of NIS and the use of chart review, which was carried out retrospectively and bears therefore the risk of selection bias. Furthermore, it must be taken into account that patients referred to a specialized dedicated nutrition-fatigue clinic are likely to have a higher symptom load. Also, the awareness of healthcare professionals in a specialized clinic may result in higher frequency of symptom assessment and treatment. Therefore, the relative impact of the checklist cannot be conclusively derived from our data.

The results of our study show that the awareness for NIS rise with the use of the NIS checklist, and it seems to trigger more therapeutic interventions compared to the matched control patients who are treated with standard care in the oncological outpatient clinic. In view of the long list of potential NIS, further research is needed on the relative importance of the single symptoms. Intervention studies are also needed to evaluate the impact of interventional management of NIS on improving nutritional intake. Standardization of NIS assessment is warranted to raise awareness of these possible correctable causes.
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